This original observation was soon extended into a large series of clinical investigations (28–84) in order to assess the potency of MGMT methylation as a predictive marker in relation to alkylating therapy in different conditions of adult and pediatric gliomas, of both high and low grade according to WHO classification (85). The gene discussed is MGMT; the disease is central nervous system cancer.